# Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

> **NCT02764541** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 195 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Tamoxifen
- **DRUG:** Palbociclib
- **DRUG:** Endocrine Therapy

## Key facts

- **NCT ID:** NCT02764541
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-24
- **Primary completion:** 2022-02
- **Final completion:** 2031-04
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2025-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02764541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02764541, "Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02764541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*